secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2022-02-22T23:59:59+00:00
Accession:  0001367644-22-000009
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions: Executive Chairman retiring Apr 1; bonuses at 75% of target; Saran, Fox promoted
--------------------------------------------------------------------------------

- Fuad El-Hibri to retire as Executive Chairman effective April 1, 2022; no 2022 equity grant.
- 2021 cash bonuses paid at ~75% of target due to below-target performance; CEO Kramer received $900,000.
- Atul Saran promoted to EVP, Chief Strategy and Development Officer effective March 1, 2022.
- Jennifer Fox promoted to EVP, External Affairs, General Counsel and Corporate Secretary effective March 1, 2022.
- One-time retention equity awards granted to NEOs (excluding El-Hibri); Kramer got $900K in PSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000009/0001367644-22-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764422000009/ebs-20220215.htm
  HTML page:      https://secwatch.observer/filing/0001367644-22-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer